Back to Browse Journals » Core Evidence » Volume 5

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

Authors Rossana Berardi, Azzurra Onofri, Mirco Pistelli, et al

Published 24 September 2010 Volume 2010:5 Pages 61—76


Review by Single-blind

Peer reviewer comments 2

Rossana Berardi1, Azzurra Onofri2, Mirco Pistelli2, Elena Maccaroni2, Mario Scartozzi1, Chiara Pierantoni1, Stefano Cascinu1
1Clinica di Oncologia Medica, Università Politecnica delle Marche, Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, Italy; 2Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy

Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival (PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with wild-type K-RAS appears the better strategy for select only the patients who could benefit from the therapy with panitumumab and also may have the potential for cost savings. The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.

Keywords: colorectal cancer, EGFR; K-RAS, panitumumab

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, Cascinu S

OncoTargets and Therapy 2013, 6:563-576

Published Date: 21 May 2013

Readers of this article also read:

The interblink interval in normal and dry eye subjects

Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB

Clinical Ophthalmology 2013, 7:253-259

Published Date: 1 February 2013

A characteristic optic disc appearance associated with myopia in subjects with Graves' ophthalmopathy and in subjects with primary open-angle glaucoma

Yamazaki S, Inoue R, Tsuboi T, Kozaki A, Inoue T, Inoue T, Inoue Y

Clinical Ophthalmology 2013, 7:47-53

Published Date: 7 January 2013


Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Sustained-release G-CSF microspheres using a novel solid-in-oil-in-oil-in-water emulsion method

Liu G, Hong X, Jiang M, Yuan W

International Journal of Nanomedicine 2012, 7:4559-4569

Published Date: 17 August 2012

Safety and clinical efficacy of golimumab in the treatment of arthritides

Ismail Simsek, Yusuf Yazici

Drug, Healthcare and Patient Safety 2010, 2:169-180

Published Date: 28 September 2010

Editorial: On the diversity of biological therapeutics ||Free Paper||

Sanjay Awasthi

Biologics: Targets and Therapy 2007, 1:183-184

Published Date: 15 January 2008

Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles

James Chen Yong Kah, Kiang Wei Kho, Caroline Guat Leng Lee, Colin James Richard Sheppard, Ze Xiang Shen, et al

International Journal of Nanomedicine 2007, 2:785-798

Published Date: 15 January 2008